Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | AHR | P35869 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2928380 | 0.92 | MAPT (0.38) | RAB9AMAPTALDH1A1SMN1; SMN2NPC1 | |
| Sulfuric Acid SCHEMBL12503432 | 0.82 | APAF1 (0.36) | MAPTALDH1A1KDM4EHPGDPOLB | |
| SCHEMBL2501720 | 0.76 | MAPT (0.38) | RAB9AMAPTALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL9276225 | 0.73 | APAF1 (0.40) | POLB | |
| SCHEMBL31450545 | 0.73 | MAPT (0.38) | RAB9AMAPTALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL10983158 | 0.73 | NPC1 (0.38) | RAB9AMAPTALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL387792 | 0.73 | MAPT (0.38) | RAB9AMAPTALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL27592760 | 0.73 | MAPT (0.38) | RAB9AMAPTALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL28361348 | 0.73 | ALDH1A1 (0.37) | RAB9AMAPTALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL652529 | 0.73 | MAPT (0.39) | RAB9AMAPTALDH1A1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040072775-A1 | Enhancing the sensitivity of tumor cells to therapies | SOBOL ROBERT (US) | 2004-04-15 | — | — | US | disclosed |
| US-20020010144-A1 | Enhancing the sensitivity of tumor cells to therapies | SOBOL ROBERT (US) | 2002-01-24 | — | — | US | disclosed |
| US-20020006914-A1 | Enhancing the sensitivity of tumor cells to therapies | SOBOL ROBERT E (US) | 2002-01-17 | — | — | US | disclosed |
| US-5871923-A | Methods for screening for antimycotics | RIBOGENE, INC. (US) | 1999-02-16 | — | — | US | disclosed |
| US-5641627-A | MEASURING EXPRESSION LEVEL OF REPORTER GENE WHEN MYCOTIC CELLS ARE TREATED WITH POTENTIAL TRANSLATION(GENETIC) INHIBITORS | RIBOGENE, INC. (US) | 1997-06-24 | — | — | US | disclosed |
| EP-0769146-A2 | SCREENING FOR NUC INHIBITORS | LIGAND PHARMACEUTICALS, INC. (US) | 1997-04-23 | — | — | EP | disclosed |
| EP-0765475-A1 | SCREENING FOR CYTOKINE MODULATORS | LIGAND PHARMACEUTICALS, INC. (US) | 1997-04-02 | — | — | EP | disclosed |
| EP-0758382-A1 | ENHANCING THE SENSITIVITY OF TUMOR CELLS TO THERAPIES | SIDNEY KIMMEL CANCER CENTER (US) | 1997-02-19 | — | — | EP | disclosed |
| EP-0725818-A1 | METHODS FOR SCREENING FOR ANTIMYCOTICS | Ribogene, Inc. (US) | 1996-08-14 | — | — | EP | disclosed |
| WO-1996001430-A2 | SCREENING FOR NUC INHIBITORS | LIGAND PHARMACEUTICALS, INCORPORATED (US) | 1996-01-18 | — | — | WO | disclosed |
| WO-1995031722-A1 | SCREENING FOR CYTOKINE MODULATORS | LIGAND PHARMACEUTICALS, INC. (US) | 1995-11-23 | — | — | WO | disclosed |
| WO-1995030002-A2 | ENHANCING THE SENSITIVITY OF TUMOR CELLS TO THERAPIES | SAN DIEGO REGIONAL CANCER CENTER (US) | 1995-11-09 | — | — | WO | disclosed |
| WO-1995011969-A1 | METHODS FOR SCREENING FOR ANTIMYCOTICS | RIBOGENE, INC. (US) | 1995-05-04 | — | — | WO | disclosed |